Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Advances in IBD and Upper GI Disorders
This week's episode covers vedolizumab for ulcerative colitis, Rome V pediatric criteria updates, vonoprazan for H. pylori, PPI mucosal changes, H. pylori screening outcomes, pancreatic cancer immunotherapy, Hepatitis A epidemiology, and the CALLY index in esophageal cancer.
Bibliography
1. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Authors: Feagan BG, Rutgeerts P, Sands BE, et al.
Journal: The New England journal of medicine, 2013 Aug 22
PMID: 23964932
DOI: 10.1056/NEJMoa1215734
2. Rome V Pediatric Upper Gastrointestinal Disorders of Gut-Brain Interaction.
Authors: Rosen R, Borrelli O, Faure C, et al.
Journal: Gastroenterology, 2026 May
PMID: 41713704
DOI: 10.1053/j.gastro.2026.01.039
3. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Authors: Chey WD, Mégraud F, Laine L, et al.
Journal: Gastroenterology, 2022 Sep
PMID: 35679950
DOI: 10.1053/j.gastro.2022.05.055
4. Proton Pump Inhibitor-Related Gastric Mucosal Changes.
Authors: Kim GH
Journal: Gut and liver, 2021 Sep 15
PMID: 32327613
DOI: 10.5009/gnl20036
5. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Authors: Feagan BG, Rutgeerts P, Sands BE, et al.
Journal: The New England journal of medicine, 2013 Aug 22
PMID: 23964932
DOI: 10.1056/NEJMoa1215734
6. Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial.
Authors: Lee YC, Chiang TH, Chiu HM, et al.
Journal: JAMA, 2024 Nov 19
PMID: 39348147
DOI: 10.1001/jama.2024.14887
7. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Authors: Park W, O'Connor CA, Chou JF, et al.
Journal: Nature medicine, 2026 May
PMID: 41882405
DOI: 10.1038/s41591-026-04299-5
8. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.
Authors: Migueres M, Lhomme S, Izopet J
Journal: Viruses, 2021 Sep 22
PMID: 34696330
DOI: 10.3390/v13101900
9. Prognostic significance of the CRP-albumin-lymphocyte (CALLY) index in esophageal cancer: systematic review and meta-analysis.
Authors: Xu W, Zhan D, Wang R, et al.
Journal: PeerJ, 2026
PMID: 42199834
DOI: 10.7717/peerj.21277
Authors: Feagan BG, Rutgeerts P, Sands BE, et al.
Journal: The New England journal of medicine, 2013 Aug 22
PMID: 23964932
DOI: 10.1056/NEJMoa1215734
2. Rome V Pediatric Upper Gastrointestinal Disorders of Gut-Brain Interaction.
Authors: Rosen R, Borrelli O, Faure C, et al.
Journal: Gastroenterology, 2026 May
PMID: 41713704
DOI: 10.1053/j.gastro.2026.01.039
3. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Authors: Chey WD, Mégraud F, Laine L, et al.
Journal: Gastroenterology, 2022 Sep
PMID: 35679950
DOI: 10.1053/j.gastro.2022.05.055
4. Proton Pump Inhibitor-Related Gastric Mucosal Changes.
Authors: Kim GH
Journal: Gut and liver, 2021 Sep 15
PMID: 32327613
DOI: 10.5009/gnl20036
5. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Authors: Feagan BG, Rutgeerts P, Sands BE, et al.
Journal: The New England journal of medicine, 2013 Aug 22
PMID: 23964932
DOI: 10.1056/NEJMoa1215734
6. Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial.
Authors: Lee YC, Chiang TH, Chiu HM, et al.
Journal: JAMA, 2024 Nov 19
PMID: 39348147
DOI: 10.1001/jama.2024.14887
7. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Authors: Park W, O'Connor CA, Chou JF, et al.
Journal: Nature medicine, 2026 May
PMID: 41882405
DOI: 10.1038/s41591-026-04299-5
8. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.
Authors: Migueres M, Lhomme S, Izopet J
Journal: Viruses, 2021 Sep 22
PMID: 34696330
DOI: 10.3390/v13101900
9. Prognostic significance of the CRP-albumin-lymphocyte (CALLY) index in esophageal cancer: systematic review and meta-analysis.
Authors: Xu W, Zhan D, Wang R, et al.
Journal: PeerJ, 2026
PMID: 42199834
DOI: 10.7717/peerj.21277
